+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In vitro activity of temocillin against prevalent extended-spectrum beta-lactamases producing Enterobacteriaceae from Belgian intensive care units



In vitro activity of temocillin against prevalent extended-spectrum beta-lactamases producing Enterobacteriaceae from Belgian intensive care units



European Journal of Clinical Microbiology and Infectious Diseases 26(11): 777-783



Temocillin is a narrow spectrum penicillin with high stability to most beta-lactamases including AmpC types and extended-spectrum types (ESBLs). We have analysed its in vitro activity against 652 clinical isolates of Enterobacteriaceae prospectively collected from patients hospitalised in intensive care units at seven different university hospitals in Belgium in 2005. Strains were screened for ESBL production using cefotaxime and ceftazidime screen agar plates and by double ESBL E-tests. The MIC of temocillin and of five comparators was determined using the E-test method. ESBLs were characterized at one central laboratory by isoelectric focusing, PCR for bla genes of the SHV, TEM, and CTX-M families, and by DNA sequencing. The prevalence of ESBL-producing Enterobacteriaceae averaged 11.8% and ranged between 3.0 and 29% in the different hospitals. Meropenem exhibited the highest in vitro activity overall (mode MIC 0.064 microg; MIC(90); 0.19 microg/ml), whereas ceftazidime (MIC(90) > 256 microg/ml) and ciprofloxacin (MIC(90) > 32 microg/ml) scored the worst. Temocillin was active against more than 90% of the isolates including most AmpC- and ESBL-producing isolates. These data indicate the well preserved activity of temocillin over the years against Enterobacteriaceae and show the wide variation in prevalence of ESBL-producing Enterobacteriaceae isolates in Belgian intensive care units. Prospective clinical studies are, however, needed to validate the usefulness of temocillin in the treatment of microbiologically documented infections caused by ESBL- and/or AmpC- overproducing nosocomial Enterobacteriaceae pathogens.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053769054

Download citation: RISBibTeXText

PMID: 17668253

DOI: 10.1007/s10096-007-0370-9


Related references

Extended spectrum beta-lactamases producing germs in intensive care units. International Journal of Antimicrobial Agents 19(Suppl. 1): S97, 2002

Prospective survey of digestive tract colonization with enterobacteriaceae that produce extended-spectrum beta-lactamases in intensive care units. Journal of Hospital Infection 62(3): 386-388, 2006

Dissemination of extended-spectrum beta-lactamase-producing Enterobacteriaceae in pediatric intensive care units. Journal of Clinical Microbiology 41(10): 4836-4838, 2003

Should we screen patients for extended-spectrum beta-lactamase-producing enterobacteriaceae in intensive care units?. Infection Control and Hospital Epidemiology 30(1): 103-105, 2009

In vitro activity of fourth generation cephalosporins against enterobacteriaceae producing extended-spectrum beta-lactamases. Journal of ChemoTherapy 8(Suppl. 2): 57-62, 1996

Evaluation of in vitro activity of 9 antimicrobials and prevalence of extended spectrum beta-lactamases in strains isolated from patients in intensive care units in Brazil. Abstracts of the General Meeting of the American Society for Microbiology 99: 163, 1999

In vitro activity of meropenem and seven other beta-lactam antibiotics against K.pneumoniae and enterobacteriaceae producing beta-lactamases with extended spectrum. Pathologie-Biologie 42(5): 365-368, 1994

Ceftibuten and bactericidal kinetics. Comparative in vitro activity against Enterobacteriaceae producing extended spectrum beta-lactamases. Diagnostic Microbiology and Infectious Disease 14(1): 89-92, 1991

Monitoring the emergence of E coli and Klebsiella producing extended-spectrum beta-lactamases in Canadian intensive care units. Abstracts of the General Meeting of the American Society for Microbiology 101: 471, 2001

Bacteraemia due to extended-spectrum beta-lactamases (ESBL) and other beta-lactamases (ampC and carbapenemase) producing Enterobacteriaceae: association with health-care and cancer. Revista Espanola de Quimioterapia 28(5): 256-262, 2015

Outbreaks of extended spectrum beta-lactamase-producing Enterobacteriaceae in neonatal intensive care units: a systematic review. Archives of Disease in Childhood. Fetal and Neonatal Edition 101(1): F72-F78, 2016

Dissemination of extended-spectrum beta-lactamase-producing Enterobacteriaceae in intensive care units of a medical center in Taiwan. Microbial Drug Resistance 12(3): 203-209, 2006

Clinical features of nosocomial infections by extended-spectrum beta-lactamase-producing Enterobacteriaceae in neonatal intensive care units. Acta Paediatrica 94(11): 1644-1649, 2005

In vitro activity of the new penem men 10700 against clinical isolates of Enterobacteriaceae producing extended-spectrum beta-lactamases or inducible cephalosporinases. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 295, 1999

Control of Enterobacteriaceae producing extended-spectrum beta-lactamase in intensive care units: rectal screening may not be needed in non-epidemic situations. Infection Control and Hospital Epidemiology 25(10): 838-841, 2004